Oral Solid Dosage Contract Manufacturing Market Report 2026

The oral solid dosage contract manufacturing market size has grown strongly in recent years. It will grow from $42.39 billion in 2025 to $45.59 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to rising pressure to reduce in-house manufacturing costs, increasing complexity of oral solid dosage formulations, growing generic drug production volumes, limited internal manufacturing capacity of pharma companies, increasing reliance on third-party CMOs.

The oral solid dosage contract manufacturing market size is expected to see strong growth in the next few years. It will grow to $59.05 billion in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing demand for scalable pharmaceutical manufacturing solutions, increasing pipeline of oral solid dosage drugs, rising investment in advanced manufacturing technologies, expansion of pharmaceutical outsourcing in emerging markets, increasing need for flexible and rapid production capabilities. Major trends in the forecast period include rising outsourcing of oral solid dosage manufacturing by pharmaceutical companies, increasing demand for high-volume and cost-efficient tablet and capsule production, growing adoption of modified and controlled release oral solid dosage forms, rising focus on regulatory compliance and quality assurance in contract manufacturing, increasing preference for end-to-end manufacturing and packaging services.

The growing demand for generic drugs is expected to drive growth in the oral solid dosage contract manufacturing market in the coming years. Generic drugs are medications that are bioequivalent to brand-name drugs in terms of dosage, strength, safety, performance, quality, and intended use. The rising demand for generics is driven by patent expirations, cost-containment efforts, regulatory incentives, and expanding access to healthcare. Oral solid dosage contract manufacturing supports the production and distribution of generic drugs by leveraging contract manufacturers’ capabilities to improve operational efficiency, reduce costs, ensure high-quality production, and accelerate time-to-market. For example, in 2025, according to the U.S. Food and Drug Administration, over 35,000 generic drugs have been approved, with 9 out of 10 prescriptions filled with generics. Additionally, in November 2024, the FDA published more than 800 revised product-specific guidances for immediate-release solid oral generic drug products. The increasing demand for generics is thus driving the growth of the oral solid dosage contract manufacturing market.

Companies in the oral solid dosage contract manufacturing market are focusing on innovative solutions, such as continuous manufacturing lines, to remain competitive. Continuous manufacturing lines utilize uninterrupted production processes to enhance efficiency, quality, and flexibility in pharmaceutical production. For instance, in January 2023, WuXi STA, a China-based pharmaceutical company, launched its first continuous manufacturing line for oral solid pharmaceutical products. This facility represents a significant advancement in drug manufacturing, streamlining production timelines, reducing downtime, and accelerating the delivery of medications to patients.

In February 2025, Jabil Inc., a US-based provider of engineering, manufacturing, and supply-chain solutions, acquired Pharmaceutics International, Inc. (Pii) for $307 million. This acquisition aims to strengthen Jabil’s pharmaceutical manufacturing capabilities, particularly in oral solid dosage forms, by integrating Pii’s contract development and manufacturing services. Pharmaceutics International, Inc. is a US-based CDMO providing early-stage, clinical, and commercial manufacturing services, including oral solid dose production, aseptic filling, and lyophilization.

Major companies operating in the oral solid dosage contract manufacturing market are Evonik Industries AG, Teva Pharmaceutical Industries Ltd., Lonza Group AG, Catalent Inc., Patheon Pharma Services, Fareva Holding SA, Piramal Enterprises Limited, Hetero Drugs Limited, Siegfried Holding AG, Recipharm AB, Almac Group Limited, Aenova Holding GmbH, Jubilant Pharmova Limited, Cambrex Corporation, International Chemical Investors Group (ICIG) operates under CordenPharma, Ajinomoto Co. Inc., Hovione Holding Ltd., Alcami Corporation, NextPharma AB, Delpharm, PCI Pharma Services, Adare Pharma, Skyepharma.

Asia-Pacific was the largest region in the oral solid dosage contract manufacturing market in 2025. The regions covered in the oral solid dosage contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the oral solid dosage contract manufacturing market by increasing costs for imported active pharmaceutical ingredients, excipients, specialized machinery, and packaging materials. These impacts are most evident in tablet and capsule manufacturing segments across north america, europe, and asia-pacific, where cross-border supply chains are deeply integrated. Higher tariffs have led to cost pressures and longer lead times for CMOs and pharmaceutical clients. However, tariffs have also encouraged localization of manufacturing, investment in domestic production facilities, and stronger regional supply chain resilience.

The oral solid dosage contract manufacturing market research report is one of a series of new reports that provides oral solid dosage contract manufacturing market statistics, including oral solid dosage contract manufacturing industry global market size, regional shares, competitors with a oral solid dosage contract manufacturing market share, detailed oral solid dosage contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the oral solid dosage contract manufacturing industry. This oral solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral solid dosage contract manufacturing refers to outsourcing the production of oral solid pharmaceutical forms to third-party manufacturers. This approach allows pharmaceutical companies to focus on core activities such as research, development, and marketing, while leveraging the expertise of contract manufacturing organizations (CMOs) to efficiently produce high-quality oral solid dosage products.

The main product types in oral solid dosage contract manufacturing include tablets, capsules, powders, granules, and other forms. Tablets are small, solid masses of medicine containing an active drug and excipients. Services offered include drug product development, fill-finish manufacturing, API production, packaging and labeling, and other related applications. Therapeutic areas served include oncology, cardiovascular diseases, metabolic disorders, neurological disorders, infectious diseases, gastrointestinal diseases, and others. End users include large pharmaceutical companies as well as medium and small-sized companies.

The oral solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as formulation development, analytical and stability testing, and quality assurance and control. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral solid dosage contract manufacturing market also consists of sales of orally disintegrating tablets (ODTS), lozenges, and chewing gums. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.